HomeCompareCYT vs BTI

CYT vs BTI: Dividend Comparison 2026

CYT yields 66.23% · BTI yields 5.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CYT wins by $842.2K in total portfolio value
10 years
CYT
CYT
● Live price
66.23%
Share price
$3.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$880.0K
Annual income
$221,634.45
Full CYT calculator →
BTI
BTI
● Live price
5.40%
Share price
$58.26
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.8K
Annual income
$2,802.29
Full BTI calculator →

Portfolio growth — CYT vs BTI

📍 CYT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYTBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYT + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CYT pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYT
Annual income on $10K today (after 15% tax)
$5,629.14/yr
After 10yr DRIP, annual income (after tax)
$188,389.28/yr
BTI
Annual income on $10K today (after 15% tax)
$459.05/yr
After 10yr DRIP, annual income (after tax)
$2,381.95/yr
At 15% tax rate, CYT beats the other by $186,007.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYT + BTI for your $10,000?

CYT: 50%BTI: 50%
100% BTI50/50100% CYT
Portfolio after 10yr
$458.9K
Annual income
$112,218.36/yr
Blended yield
24.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

CYT
No analyst data
Price Target
$2.00
-33.8% upside vs current
Range: $2.00 — $2.00
Altman Z
9.4
Piotroski
1/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.3% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYT buys
0
BTI buys
0
No recent congressional trades found for CYT or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYTBTI
Forward yield66.23%5.40%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$880.0K$37.8K
Annual income after 10y$221,634.45$2,802.29
Total dividends collected$742.8K$14.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst price target$2.00$40.00

Year-by-year: CYT vs BTI ($10,000, DRIP)

YearCYT PortfolioCYT Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$17,323$6,622.52$11,301$601.08+$6.0KCYT
2$29,256$10,721.37$12,799$706.58+$16.5KCYT
3$48,227$16,923.00$14,527$832.38+$33.7KCYT
4$77,675$26,071.48$16,527$982.75+$61.1KCYT
5$122,356$39,243.54$18,846$1,162.95+$103.5KCYT
6$188,694$57,773.40$21,545$1,379.49+$167.1KCYT
7$285,170$83,268.01$24,694$1,640.41+$260.5KCYT
8$422,742$117,609.16$28,378$1,955.69+$394.4KCYT
9$615,273$162,940.02$32,702$2,337.79+$582.6KCYT
10$879,977$221,634.45$37,794$2,802.29+$842.2KCYT

CYT vs BTI: Complete Analysis 2026

CYTStock

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.

Full CYT Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this CYT vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYT vs SCHDCYT vs JEPICYT vs OCYT vs KOCYT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.